NCT04557280View on ClinicalTrials.gov

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

December 19, 2020

Study Completion Date

December 19, 2020

Conditions
Healthy Subjects
Interventions
COMBINATION_PRODUCT

Selatogrel

A single subcutaneous injection of 16 mg.

DRUG

Selatogrel

A single subcutaneous injection of 16 mg.

Trial Locations (1)

66212

Altasciences Clinical Kansas, Inc, Overland Park

All Listed Sponsors
lead

Viatris Innovation GmbH

INDUSTRY

NCT04557280 - A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects | Biotech Hunter | Biotech Hunter